Bioptik Technology (ROCO:4161) Debt-to-Equity : 0.59 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Bioptik Technology Debt-to-Equity?

Bioptik Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$372.8 Mil. Bioptik Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$138.6 Mil. Bioptik Technology's Total Stockholders Equity for the quarter that ended in Sep. 2024 was NT$869.9 Mil. Bioptik Technology's debt to equity for the quarter that ended in Sep. 2024 was 0.59.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bioptik Technology's Debt-to-Equity or its related term are showing as below:

ROCO:4161' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.76 Max: 1.05
Current: 0.59

During the past 13 years, the highest Debt-to-Equity Ratio of Bioptik Technology was 1.05. The lowest was 0.08. And the median was 0.76.

ROCO:4161's Debt-to-Equity is ranked worse than
73.58% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs ROCO:4161: 0.59

Bioptik Technology Debt-to-Equity Historical Data

The historical data trend for Bioptik Technology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioptik Technology Debt-to-Equity Chart

Bioptik Technology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.88

0.99

0.93

0.64

Bioptik Technology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.70	0.64	0.65	0.61	0.59

Competitive Comparison of Bioptik Technology's Debt-to-Equity

For the Medical Devices subindustry, Bioptik Technology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioptik Technology's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bioptik Technology's Debt-to-Equity falls into.

Bioptik Technology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bioptik Technology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(368.032	+	155.21)	/	819.341
	=	0.64

Bioptik Technology's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(372.773	+	138.598)	/	869.868
	=	0.59

Bioptik Technology (ROCO:4161) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bioptik Technology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bioptik Technology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioptik Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioptik Technology Inc (ROCO:4161) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057

Website

http://www.bioptik.com.tw

Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.

Bioptik Technology Headlines

No Headlines